Cognitive Speed in Neurodegenerative Disease: Comparing Mean Rate and Inconsistency Within and Across the Alzheimer’s and Lewy Body Spectra in the COMPASS-ND Study
Journal of Alzheimer's Disease · 2024
DOI: 10.3233/jad-240210 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Journal of Alzheimer's Disease, 2024. Verfasst von H Sebastian Caballero und 8 weiteren Autor:innen. Beteiligte Einrichtung: Neuroscience and Mental Health Institute, University of Alberta, Edmonton, AB, Canada. Hauptthemen laut MEDLINE: Lewy Body Disease, Alzheimer Disease, Cognitive Dysfunction, Reaction Time. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 136 Literaturangaben.
Themen: Demenz
Abstract (Originalsprache)
Background
Alzheimer’s disease (AD) and Lewy body disease (LBD) are characterized by early and gradual worsening perturbations in speeded cognitive responses.
Objective
Using simple and choice reaction time tasks, we compared two indicators of cognitive speed within and across the AD and LBD spectra: mean rate (average reaction time across trials) and inconsistency (within person variability).
Methods
The AD spectrum cohorts included subjective cognitive impairment (SCI, n = 28), mild cognitive impairment (MCI, n = 121), and AD (n = 45) participants. The LBD spectrum included Parkinson’s disease (PD, n = 32), mild cognitive impairment in PD (PD-MCI, n = 21), and LBD (n = 18) participants. A cognitively unimpaired (CU, n = 39) cohort served as common benchmark. We conducted multivariate analyses of variance and discrimination analyses.
Results
Within the AD spectrum, the AD cohort was slower and more inconsistent than the CU, SCI, and MCI cohorts. The MCI cohort was slower than the CU cohort. Within the LBD spectrum, the LBD cohort was slower and more inconsistent than the CU, PD, and PD-MCI cohorts. The PD-MCI cohort was slower than the CU and PD cohorts. In cross-spectra (corresponding cohort) comparisons, the LBD cohort was slower and more inconsistent than the AD cohort. The PD-MCI cohort was slower than the MCI cohort. Discrimination analyses clarified the group difference patterns.
Conclusions
For both speed tasks, mean rate and inconsistency demonstrated similar sensitivity to spectra-related comparisons. Both dementia cohorts were slower and more inconsistent than each of their respective non-dementia cohorts.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Neuroscience and Mental Health Institute, University of Alberta, Edmonton, AB, Canada.
- Department of Psychology, University of Alberta, Edmonton, AB, Canada.
- Department of Medicine (Neurology), University of Alberta, Edmonton, AB, Canada.
- Department of Psychology, University of Victoria, Victoria, BC, Canada.
- Department of Psychology, Concordia University, Montréal, QC, Canada.
- Lawson Health Research Institute, London, ON, Canada.
Zitieren
APA
Caballero, H. S., McFall, G. P., Gee, M., MacDonald, S., Phillips, N. A., Fogarty, J., Montero-Odasso, M., Camicioli, R., & Dixon, R. A. (2024). Cognitive Speed in Neurodegenerative Disease: Comparing Mean Rate and Inconsistency Within and Across the Alzheimer’s and Lewy Body Spectra in the COMPASS-ND Study. Journal of Alzheimer's Disease. https://doi.org/10.3233/jad-240210
Vancouver
Caballero HS, McFall GP, Gee M, MacDonald S, Phillips NA, Fogarty J, et al. Cognitive Speed in Neurodegenerative Disease: Comparing Mean Rate and Inconsistency Within and Across the Alzheimer’s and Lewy Body Spectra in the COMPASS-ND Study. Journal of Alzheimer's Disease. 2024. doi:10.3233/jad-240210
BibTeX
@article{Caballero2024,
author = {Caballero, H Sebastian and McFall, G Peggy and Gee, Myrlene and MacDonald, Stuart and Phillips, Natalie A and Fogarty, Jennifer and Montero-Odasso, Manuel and Camicioli, Richard and Dixon, Roger A},
title = {Cognitive Speed in Neurodegenerative Disease: Comparing Mean Rate and Inconsistency Within and Across the Alzheimer’s and Lewy Body Spectra in the COMPASS-ND Study},
journal = {Journal of Alzheimer's Disease},
year = {2024},
doi = {10.3233/jad-240210}
}
EUVIMED